ICD-10 Logo
ICDxICD-10 Medical Coding
ICD-10 Logo
ICDxICD-10 Medical Coding
ICD 10 CodesDiagnoses
ICD 10 CodesDiagnoses
ICD-10 Logo
ICDxICD-10 Medical Coding

Comprehensive ICD-10-CM code reference with AI-powered search capabilities.

© 2025 ICD Code Compass. All rights reserved.

Browse

  • All Chapters
  • All Categories
  • Diagnoses

Tools

  • AI Code Search
ICD-10-CM codes are maintained by the CDC and CMS. This tool is for reference purposes only.
v1.0.0
ICD-10 Guide
ICD-10 CodesD07.3

D07.3

Billable

Carcinoma in situ of other and unspecified female genital organs

BILLABLE STATUSYes
IMPLEMENTATION DATEOctober 1, 2015
LAST UPDATED09/05/2025

Code Description

ICD-10 D07.3 is a billable code used to indicate a diagnosis of carcinoma in situ of other and unspecified female genital organs.

Key Diagnostic Point:

Carcinoma in situ (CIS) of the female genital organs refers to a localized cancer that has not invaded surrounding tissues. This condition can occur in various sites within the female genital tract, including the cervix, vulva, vagina, and other unspecified areas. CIS is characterized by abnormal cell growth that is confined to the epithelial layer and has not metastasized. Early detection through routine screenings, such as Pap smears, is crucial for effective management. The prognosis for patients diagnosed with CIS is generally favorable, especially when detected early. However, without appropriate surveillance and treatment, there is a risk of progression to invasive cancer. Treatment options may include surgical excision, laser therapy, or topical chemotherapy, depending on the location and extent of the carcinoma. Regular follow-up is essential to monitor for any signs of progression or recurrence, making it a critical aspect of patient management.

Code Complexity Analysis

Complexity Rating: Medium

Medium Complexity

Complexity Factors

  • Variability in documentation across specialties
  • Need for precise localization of the carcinoma
  • Differentiation from other types of neoplasms
  • Potential for progression to invasive cancer

Audit Risk Factors

  • Inadequate documentation of the site of carcinoma
  • Failure to document follow-up care and surveillance
  • Misclassification of carcinoma in situ as invasive cancer
  • Lack of clarity on treatment plans

Specialty Focus

Medical Specialties

Gynecology

Documentation Requirements

Detailed documentation of the site, size, and characteristics of the carcinoma, as well as treatment plans and follow-up care.

Common Clinical Scenarios

Routine screenings, abnormal Pap results, and management of CIS.

Billing Considerations

Ensure accurate coding based on biopsy results and treatment modalities.

Oncology

Documentation Requirements

Comprehensive treatment plans, including surgical and non-surgical interventions, and follow-up protocols.

Common Clinical Scenarios

Management of patients with a history of CIS and monitoring for progression.

Billing Considerations

Collaboration with pathology reports to confirm diagnosis and staging.

Coding Guidelines

Inclusion Criteria

Use D07.3 When
  • According to ICD
  • 10 coding guidelines, D07
  • 3 should be used when the carcinoma is confirmed as in situ and the specific organ is not documented
  • Coders should ensure that the diagnosis is supported by pathology reports and clinical documentation

Exclusion Criteria

Do NOT use D07.3 When
No specific exclusions found.

Related ICD-10 Codes

Related CPT Codes

58100CPT Code

Total abdominal hysterectomy

Clinical Scenario

Used when surgical intervention is required for carcinoma in situ.

Documentation Requirements

Operative reports detailing the procedure and findings.

Specialty Considerations

Gynecological oncology may require additional documentation for staging.

ICD-10 Impact

Diagnostic & Documentation Impact

Enhanced Specificity

ICD-10 Improvements

The transition to ICD-10 has allowed for greater specificity in coding carcinoma in situ, improving the accuracy of patient records and treatment plans. D07.3 provides a clear classification for cases that do not specify the site, which was less defined in ICD-9.

ICD-9 vs ICD-10

The transition to ICD-10 has allowed for greater specificity in coding carcinoma in situ, improving the accuracy of patient records and treatment plans. D07.3 provides a clear classification for cases that do not specify the site, which was less defined in ICD-9.

Reimbursement & Billing Impact

The transition to ICD-10 has allowed for greater specificity in coding carcinoma in situ, improving the accuracy of patient records and treatment plans. D07.3 provides a clear classification for cases that do not specify the site, which was less defined in ICD-9.

Resources

Clinical References

  • •
    ICD-10-CM Official Guidelines for Coding and Reporting

Coding & Billing References

  • •
    ICD-10-CM Official Guidelines for Coding and Reporting

Frequently Asked Questions

What is the significance of carcinoma in situ?

Carcinoma in situ is a critical early stage of cancer that has not invaded surrounding tissues. Early detection and treatment can prevent progression to invasive cancer, making it essential for patient management.